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Quinidine Purpura: Evidence That Glycoprotein V Is a Target Platelet Antigen
By Raphael B. Stricker and Marc A. Shuman
Quinidine-induced thrombocytopenia has been associated
with both immune complex and autoantibody binding to
platelets. In the present study, serum antibody from six of
six patients with quindine purpura was shown by immuno-
blotting to bind to a single platelet membrane protein of
mol wt 80,000. This target protein was absent from
Bernard-Soulier (BSS) platelets. F(ab)2 prepared from one
patient’s serum also bound to this protein, indicating
autoantibody rather than immune complex binding to the
target antigen. Antibody binding to the 8O-kd protein was
preserved after treatment of platelets with concentrations
QUINIDINE PURPURA is an immune-mediated
thrombocytopenia induced by quinidine or its metabo-
lites.’ Although previous studies have postulated an immune
complex mechanism of platelet destruction in this disease’￿2
more recent work indicates that autoantibody binding to
platelets may be the causative mechanism.3’4 The target
platelet antigen in quinidine purpura has been reported to be
glycoprotein lb (GPIb), based on immunoprecipitation stud-
ies in one patient5 and binding inhibition studies using
alboantibody against GPIb to block platelet lysis by drug-
dependent antibody in another patient.6 However, a direct
relationship between GPIb and quinidine-dependent anti-
body has not been established.’
We previously used immunobbotting with patient serum to
define target platelet antigens in homosexual men with
immune thrombocytopenic purpura7 and in a patient with
acquired Bernard-Soulier syndrome (BSS).’ In the present
study, we used immunobbotting of platelet proteins to deter-
mine the nature of target platelet antigen(s) in quinidine-
induced thrombocytopenia.
MATERIALS AND METHODS
Serum samples and F(ab)2 preparation. Blood was obtained
from six patients with quinidine-induced thrombocytopenia. All
patients were taking quinidine sulfate, and all were thrombocyto-
penic at the time that blood was drawn. The platelet counts returned
to normal in all six patients following discontinuation of the drug.
Three of the patient samples had serum quinidine levels of 0.6, 0.7,
and I .7 mg/dL, whereas the other three samples had undetectable
levels (<0.2 mg/dL) at the time that blood was drawn. Sera from
three patients with thrombocytopenia due to phenytoin or trimetho-
prim/sulfamethoxazole and from six quinidine-treated patients with
normal platelet counts were used as controls. The quinidine-treated
controls had serum drug levels ranging from 0.9 to 5.1 mg/dL.
Drug-induced thrombocytopenia was documented by an indirect
platelet antibody assay showing binding of serum antibody to control
platelets in the presence of the specific drug.9 Rabbit antisera
against GPV’#{176} and GPIb were generously provided by Dr David R.
Phillips and Dr Joan Fox of the Gladstone Institute Foundation, San
Francisco. F(ab)2 fragments were prepared as previously described7
from the staphylococcal protein A-purified bgG fraction of blood
from one patient with quinidine-induced thrombocytopenia. The
IgG was used at a concentration of 2 mg/mL and the F(ab)2 was
used at a concentration of 3 mg/mL for immunobbotting.
Platelet and GPVpreparation. Control and BSS platelets were
isolated as previously described.7 The BSS platelets” were gener-
ously provided by Dr Margaret Johnson of the Medical Center of
Delaware, Newark. Trypsin-treated platelets were prepared accord-
of trypsin or chymotrypsin that completely removed glyco-
protein lb (GPIb). Preincubation of platelet proteins with
one patient’s serum blocked binding of a polyclonal rabbit
antibody against glycoprotein V (GPV), indicating that
these antibodies recognize the same antigen. By wheat
germ affinity chromatography, GPV was shown to copurify
with GPlb. Quinidine-induced antibody bound to the wheat
germ-purified GPV but not to GPIb. We conclude that
quinidine purpura is associated with autoantibody directed
against platelet GPV.
a) 1986 by Grune & Stratton. Inc.
ing to the method of Phillips.’2 Chymotrypsin-treated platelets were
prepared by the method of Greenberg et al’3 using 10 U/mL of
a-chymotrypsin (Sigma, St Louis). GPV was partially purified and
concentrated by a modification of the method of Berndt and
Phillips’0: freshly prepared platelets (4 x l09/mL) were incubated
with elution buffer (0.01 mol/L of Hepes, I mmol/L of EDTA, 0.3
mol/L of NaCI, ph 7.6) at 37 #{176}C for 24 hours. The resultant platelet
eluate was dialyzed and concentrated overnight at 4 #{176}C against
phosphate-buffered saline (PBS) containing 5 mmol/L of EDTA
and 10% polyethylene glycol. The eluate was then suspended in
PBS-EDTA at a protein concentration of 1.1 mg/mL. Protein
measurements were made by a modified Lowry technique.’4 The
GPV preparation was then solubilized in 2% sodium dodecyl sulfate
(SDS) sample buffer. It was subsequently shown to be free of GPIb
by immunoblotting with rabbit anti-GPIb antibody (data not
shown).
Wheat germ affinity chromatography was performed according to
the method of Nachman et al.’5 Normal platelets (4 x 109/mL)
were solubilized in 1% SDS. The SDS was then diluted to 0.05% in a
solution containing 5 mmol/L of EDTA and 1% (vol/vol) aprotinin,
and the solubilized platelets were layered over a column of wheat
germ coupled to agarose (E-Y Labs, San Mateo, Califl. Elution was
performed using 0.2 mob/L of N-acetylglucosamine. The nonadher-
ent fraction (WGA I) and adherent N-acetylglucosamine-eluted
fraction (WGA II) were dialyzed against PBS-EDT1￿ -1% aprotinin
and solubilized in 2% SDS at equivalent protein concentrations (3.5
mg/mL).
Immunoblotting. Fifty-microbiter aliquots of platelet samples,
partially purified GPV, WGA I, or WGA II, were ebectrophoresed in
SDS-8% polyacrylamide gels or SDS-5% polyacrylamide gels under
nonreducing conditions.7 The samples were transferred to nitrocellu-
lose and blotted as previously described.7 Patient serum samples
were diluted 1:100 in Tris-buffered saline (TBS) containing 1%
gelatin. Rabbit serum was diluted 1:500 in the same buffer.
Blocking experiments were performed as follows: nitrocellubose
strips were incubated with patient or control serum for one hour,
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followed by washing in TBS and incubation with rabbit anti-GPV
for two hours. Binding of rabbit antibody to GPV was detected with
biotin-conjugated goat F(ab)2 anti-rabbit IgG (Tago, Burlingame,
Calif) and avidin-peroxidase (Cappel, Malvern, Pa). The anti-rabbit
antibody did not react with human IgG.
RESULTS
Figure 1 shows the results of immunobbotting using serum
incubated with platelet proteins that have been transferred to
nitroceblubose after ebectrophoresis in SDS-8% pobyacryl-
amide gels. In contrast to control serum (bane A), antibody
binding to a platelet protein with a mob wt of 80,000 was
detected using patient serum (lane B). Identical results were
obtained with all six sera from patients with quinidine-
induced thrombocytopenia. Sera from the six quinidine-
treated controls and from the three patients with other
drug-induced thromobcytopenias showed no antibody bind-
ing to this antigen (data not shown). Binding did not occur
when the patient’s serum was incubated with BSS platelets
(lane C), indicating absence of the target antigen on these
platelets. Incubation of patient serum with partially purified
GPV revealed binding to a protein of identical mob wt (bane
D). F(ab)2 (3 mg/mL) prepared from serum of the only
patient tested also bound to this target protein (lane E). No
antibody binding was seen in the region of GP IX (mol wt
22,000, not shown).
Figure 2 shows the results of immunobbotting with platelet
proteins that have been transferred to nitrocellubose after
electrophoresis in SDS-5% polyacrylamide gels. In lane A,
patient serum again shows antibody binding to an 80-kd
protein at the bottom of the gel. The band at 150 kd
corresponds to IgG in the platelet preparation. This band is
also detected when BSS platelets are incubated with patient
serum, but the 80-kd band is not seen in these platelets (bane
B). The 80-kd band corresponds to concentrated GPV, seen
A B C DE
- 80 KD
Fig 1 . Identification of antibody against glycoprotein V (GPV)
in patients with quinidine purpura. Solubilized platelet proteins
were subjected to sodium dodecyl sulfate (SDS)-8% polyacryl-
amide gel electrophoresis (PAGE). transferred to nitrocellulose.
and incubated in stepwise fashion with test serum or F(ab)2,
biotin-conjugated goat F(ab)2 anti-human 1g. and avidin-peroxi-
dase. Lane A, control platelets incubated with control serum; lane
B, control platelets incubated with patient serum; lane C. Bernard-
Soulier syndrome (BSS) platelets incubated with patient serum;
lane D, purified GPV incubated with patient serum; lane E. control
platelets incubated with patient F(ab)2 (3 mg/mI). Note binding of
patient antibody and F(ab)3 to 80-kd control platelet protein and
purified GPV, but not to BSS platelets (arrow).
Fig 2. Comparison of antibody binding to glycoproteins V and
lb (GPV and GPIb). Platelet proteins or partially purified GPV were
subjected to sodium dodecyl sulfate (SDS) 5% polyacryamide gel
electrophoresis (PAGE), transferred to nitrocellulose, and incu-
bated with patient serum or rabbit anti-GPIb antibody as follows:
lane A, control platelets incubated with patient serum; lane B,
Bernard-Soulier syndrome (BSS) platelets incubated with patient
serum; lane C, partially purified GPV incubated with patient serum;
lane D, control platelets incubated with anti-GPIb antibody. Note
antibody binding to 80-kd protein in control platelets but not in
BSS platelets and corresponding to GPV. Band at 150-kd in lanes A
and B corresponds to lgG in platelet preparations. Serum antibody
does not bind to GPIb (mol wt 1 70,000) in control platelets (lane
A).
in bane C after incubation with patient serum. In bane D,
incubation of platelet proteins with rabbit anti-GPIb yields a
band at 170 kd. This band is not seen in lane A, indicating
that the patient’s antibody does not bind to GPIb.
Figure 3 shows binding and blocking experiments using
rabbit anti-GPV antibody. In contrast to control rabbit
serum (lane A), the anti-GPV antiserum bound to an 80-kd
protein detected in control platelets (lane B) and in the
partially purified GPV preparation (bane C). In the blocking
experiment, control platelet protein (lane E) or purified GPV
Fig 3. Binding of rabbit antiglycoprotein V (GPV) on immuno-
blots. Lane A, platelets incubated with control rabbit serum; lane
B, platelets incubated with anti-GPV antibody; lane C. purified
GPV incubated with anti-GPV antibody; lane D. Bernard-Soulier
syndrome (BSS) platelets incubated with anti-GPV antibody; lane
E, platelets incubated with patient serum followed by anti-GPV
antibody; lane F, purified GPV incubated with patient serum
followed by anti-GPV. Rabbit antibody binding was detected using
biotin-conjugated goat antirabbit IgG. Note anti-GPV antibody
binding to 80-kd protein (arrow) that is blocked by preincubation
with patient serum in lanes E and F.
For personal use only. on October 31, 2014.  by guest    www.bloodjournal.org From QUINIDINE PURPURA AND GLYCOPROTEIN V 1379
quinidine purpura involved binding of drug-antibody corn-
(lane F) was first incubated with patient serum, followed by
rabbit anti-GPV. Binding of the rabbit antiserum was abol-
ished by preincubation with patient serum, indicating that
both antibodies recognize the same binding site. Preincuba-
tion with either normal human serum or serum from a
patient with phenytoin-induced thrombocytopenia failed to
block binding of the rabbit antibody to GPV (data not
shown).
Figure 4 shows binding of patient serum and rabbit
anti-GPV to platelet proteins eluted from a wheat germ
affinity column. The patient’s serum and anti-GPV antibody
bound to an 80-kd antigen in the WGA II (adherent)
fraction (lanes B and D) but not in the WGA I (nonadher-
ent) fraction (lanes A and C). The WGA II fraction also
contained a I 70-kd protein that reacted with rabbit anti-
GPIb (data not shown). Thus, GPV copurifies with GPIb
when both are subjected to wheat germ affinity chromatog-
raphy. Binding of rabbit antibody to GPV was blocked by
preincubation with patient serum (lane E), again showing
that both antibodies bind to GPV. Preincubation with control
human serum did not block rabbit antibody binding to GPV
(data not shown). For comparison, binding of patient IgG (2
mg/mL) to GPV in platelets is shown in lane F.
Figure 5 shows the results of immunoblotting using tryp-
sin-treated and chymotrypsin-treated platelets. In contrast to
control platelets (lane A), rabbit anti-GPIb antibody failed
to bind to trypsin-treated platelets (lane B) or to chymotryp-
sin-treated platelets (bane C). However, patient serum still
bound to GPV in both of these platelet preparations (lanes E
and F), indicating that GPV is not removed by exposure to
trypsin or chymotrypsin. The band at 1 50 kd in lanes D
through F again corresponds to IgG in the platelet prepara-
“-80 KD
Fig 4. Immunoblot of antibody binding to wheat germ-purified
platelet glycoproteins. Control platelets were solubilized and sub-
jected to wheat germ affinity chromatography. The nonadherent
(WGA I) and adherent (WGA II) platelet glycoprotein fractions
were subjected to sodium dodecyl sulfate-polyacrylamide gel
electrophoresis (SDS-PAGE). transferred to nitrocellulose, and
incubated with patient serum or rabbit anti-GPV antibody. Lane A.
WGA I incubated with patient serum; lane B. WGA II incubated
with patient serum; lane C. WGA I incubated with anti-GPV
antibody; lane D. WGA II incubated with anti-GPV antibody; lane E,
WGA II incubated with patient serum followed by rabbit anti-GPV
antibody and biotin-conjugated goat anti-rabbit lgG; lane F. control
platelets incubated with patient lgG (2 mg/mI). Note binding to
80-kd glycoprotein in WGA II fraction that corresponds to GPV in
platelet preparation (arrow). Binding of rabbit anti-GPV antibody
to WGA II is blocked by preincubation with patient serum (lane
E).
Fig 5. Immunoblot of platelets after exposure to trypsin or
chymotrypsin. Control platelets were treated with trypsin or
chymotrypsin. The platelet proteins were then subjected to
sodium dodecyl sulfate (SDS) 5% polyacrylamide gel electrophore-
sis (PAGE). transferred to nitrocellulose, and incubated with rabbit
anti-glycoprotein lb (GPIb) or patient serum. Anti-GPIb was incu-
bated with untreated platelets (lane A), trypsin-treated platelets
(lane B). or chymotrypsin-treated platelets (lane C). Patient serum
was incubated with untreated platelets (lane D). trypsin-treated
platelets (lane D). or chymotrypsin-treated platelets (lane F). Note
that rabbit antibody binding to GPIb (mol wt 170.000) is abolished
by trypsin or chymotrypsin treatment. but patient antibody binding
to glycoprotein V (GPV) (mol wt 80.000) is retained. Bands at
1 50.000 daltons in lanes D through F correspond to IgG in platelet
preparations detected by anti-human immunoglobulin.
tions. Thus, enzyme-treated platelets that are deficient in
GPIb retain the ability to bind anti-GPV antibody.
DISCUSSION
Although quinidine-induced thrombocytopenia is a webb-
described entity, the target platelet antigen and the mecha-
nism of platelet destruction in this disease remain controver-
sial. Previous reports have suggested that a drug-antibody
immune complex binds to the platelet F(c) receptor, result-
ing in destruction of platelets as “innocent bystanders.”2
However, recent findings are inconsistent with the innocent
bystander hypothesis. Kunicki et a16 showed that binding of
heat-aggregated human IgG to the F(c) receptor on platelets
failed to inhibit binding of quinidine-dependent antibody.
Conversely, formalin fixation of platelets under conditions
that do not inhibit binding of immune complexes abolished
binding of drug-induced antibody.’ Furthermore, Christie et
a13 demonstrated that anti-F(ab)2 antibody inhibited binding
of quinidine-dependent antibody to platelets, suggesting the
presence of autoantibody rather than immune complex bind-
ing to the target antigen. Similar observations were made by
Smith et a14 using a different technique.
Initial studies showed that BSS platelets failed to bind
antibody from patients with quinidine purpura,’ suggesting
that the binding site is GPIb, known to be deficient in these
platelets. In addition, Degos et al’6 demonstrated immuno-
precipitation of radiolabeled GPIb by an IgG alloantibody
isolated from the serum of a BSS patient. This alloantibody
blocked binding of quinidine-dependent antibody to normal
platelets in the only patient studied,6 further implicating
GPIb as the antibody binding site. Because GPIb was
reported to be an immune complex receptor on platelets,’7 it
was postulated that the mechanism of platelet destruction in
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plex to this protein. However, when platelets were treated
with concentrations of trypsin or chymotrypsin that com-
pletely removed GPIb, they retained 80% of the receptor
activity for quinidine-dependent antibody.’ Based on this
observation, Kunicki et al suggested that a membrane pro-
tein other than GPIb may be responsible for drug-induced
antibody binding in quinidine purpura.’
Our results suggest that GPV is a target platelet antigen
recognized by quinidine-associated antibody. GPV has three
characteristics that have been attributed to the receptor for
this antibody. First, the glycoprotein is missing from BSS
platelets,” explaining the absence of antibody binding to
these platelets. Second, we have found that removal of GPIb
using trypsin or chyrnotrypsin fails to remove GPV from
normal platelets. These GPIb-deficient platelets retain the
ability to bind quinidine-induced anti-GPV antibody. Third,
our results using wheat germ affinity chromatography dem-
onstrate for the first time that GPV copurifies with GPIb in
the wheat germ-adherent fraction. Kunicki et al previously
showed that 80% of antigenic activity for quinidine-depen-
dent antibody can be isolated in the wheat germ-adherent
platelet membrane fraction.6 Our findings suggest that at
beast in the patients we have studied, this antigenic activity is
due to the presence ofGPV rather than GPIb in the adherent
fraction. However, we have not excluded the possibility that
quinidine induces antibody formation against GPIb as well
asGPV.
Previous studies have shown that quinidine-dependent
antibody binds to whole platelets”3’4 or to Triton-solubibized
platelet membranes56 only in the presence of quinidine. Our
results using platelet membranes fixed in nitrocellubose show
that binding of the anti-GPV antibody occurs with serum,
purified lgG, and F(ab)2 in the apparent absence of the drug.
Addition ofexogenous quinidine (I mmob/L final concentra-
tion) to the incubation mixture did not increase antibody
binding to GPV on the nitrocelbubose membranes. A possible
explanation for antibody binding in the absence of drug is
that platelet membrane fixation in nitrocellulose may render
the target antigen more accessible to the antibody, even in
the absence of quinidine. An attractive hypothesis based on
our findings is that quinidine causes platelet destruction in
two steps: (I ) it induces autoantibody production against
GPV, and (b) it directly interacts with the platelet mem-
brane to make GPV more accessible to the antibody.
Although antibody binding to intact platelets or to soluble
I. Kunicki TJ, Christie Di, Aster RH: The human platelet
receptor(s) for quinine/quinidine-dependent antibodies. Blood Cells
9:293, 1983
2. Christie DJ, Aster RH: Drug-antibody-platelet interaction in
quinine- and quinidine-induced thrombocytopenia. J Clin Invest
70:989, 1982
3. Christie DJ, Mullen PC, Aster RH: Fab-mediated binding of
drug-dependent antibodies to platelets in quinidine- and quinine-
induced thromobcytopenia. J Clin Invest 75:310, 1985
4. Smith ME, Jordan JV, Reid DM, Jones CE, Shulman NA:
Drug-antibody binding to platelets is mediated by the Fab domain
and is not Fc-dependent. Blood 64:91a, 1984 (abstr)
5. Chong BH, Berndt MC, Koutts J, Castaldi PA: Quinidine-
membranes requires both steps, binding to membranes fixed
in nitrocellubose does not require the presence of drug. This
hypothesis is also consistent with the “neoantigen” model
proposed by Christie et al3: The putative neoantigen corre-
sponds to GPV exposed by quinidine. Further testing of
purified antibody and soluble GPV in the presence or
absence of the drug may resolve this issue.
Another possibility is that quinidine purpura involves
binding of both drug-dependent and non-drug-dependent
antibodies to platelets, as suggested in two recent reports.’9’2#{176}
Drug-dependent antibody binding may not be detectable by
the immunobbot technique. Whether non-drug-dependent
anti-GPV antibody plays a role in the pathogenesis of
thrombocytopenia is unclear. We believe that this antibody is
significant, however, since it was present in all six patients
with quinidine purpura but in none of the six quinidine-
treated patients with normal platelet counts. The relation-
ship of the anti-GPV antibody to the development of throm-
bocytopenia must still be determined.
Our results are consistent with F(ab)2 binding to a target
platelet antigen in at least one patient. How quinidine
induces autoantibody formation against platelets must still
be determined. We have found serum antibody against GPV
in two patients with acute leukemia refractory de novo to
platelet transfusions, as well as in two children with ITP
(R.B. Stricker and M.A. Shuman, unpublished observations,
1985). In addition, Beardsley et al2’ recently demonstrated
antibodies against GPV in three children with varicella-
associated thrombocytopenia. Thus, antibody production
against GPV may result from an alteration in immune
surveillance induced by a specific drug or underlying disease.
This type of immune dysfunction has been invoked to explain
the lupuslike syndrome associated with quinidine and other
drugs.22’23 The mechanism of autoantibody induction by
quinidine requires further study.
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